| Original language | English |
|---|---|
| Pages (from-to) | 215-216 |
| Number of pages | 2 |
| Journal | Schizophrenia Research |
| Volume | 189 |
| DOIs | |
| State | Published - Nov 2017 |
| Externally published | Yes |
Bibliographical note
Funding Information:Y. Weinstein was partly supported by a Tauber Foundation grant.
Funding Information:
Weinstein, Roe and Gelkopf report no disclosure. Levine received no support for this study and in unrelated work author Levine has received research support, and/or consultancy fees and/or travel support from F. Hoffmann-La Roche, Shire Pharmaceuticals (45031) and Eli Lilly (8635).
Funding
Y. Weinstein was partly supported by a Tauber Foundation grant. Weinstein, Roe and Gelkopf report no disclosure. Levine received no support for this study and in unrelated work author Levine has received research support, and/or consultancy fees and/or travel support from F. Hoffmann-La Roche, Shire Pharmaceuticals (45031) and Eli Lilly (8635).
| Funders | Funder number |
|---|---|
| Tauber Foundation | |
| Eli Lilly and Company | 8635 |
| F. Hoffmann-La Roche | |
| Shire | 45031 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver